Payment overview · 2025
General Payments
$2,995.43
126 reported records · 23 companies
Healthcare provider profile · identity verified
Lazaro Rabang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · URBANDALE, IA · NPI 1649387697
Verified facts
What the public records show
CMS Open Payments records show Lazaro Rabang, MD received $2,995.43 in general payments during 2025 across 126 reported records.
PFIZER INC. accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $375.18 | 12.5% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $347.68 | 11.6% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $322.15 | 10.8% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $252.99 | 8.4% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $229.31 | 7.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $228.02 | 7.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.58 | 6.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.27 | 6.5% | 12 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $168.52 | 5.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $146.00 | 4.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.99 | 3.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $71.44 | 2.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.80 | 1.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $49.70 | 1.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.06 | 1.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.52 | 1.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.19 | 1.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.28 | 1.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.00 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.92 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.36 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.67 | 0.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $13.80 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,976.58 | 125 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $373.95 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $252.99 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $229.31 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $228.02 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $212.33 | 16 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $168.52 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $168.52 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.47 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $146.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $141.81 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $108.81 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $103.52 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $99.65 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $99.65 | 4 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.77 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.99 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $73.59 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71.44 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.15 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $49.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.52 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 349 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 266 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
349 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1104 | 276 |
| Levothyroxine Sodium | Levothyroxine Sodium | 910 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 899 | 207 |
| Furosemide | Furosemide | 680 | 128 |
| Gabapentin | Gabapentin | 625 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 587 | 127 |
| Sertraline Hcl | Sertraline Hcl | 548 | 98 |
| Losartan Potassium | Losartan Potassium | 521 | 116 |
| Lisinopril | Lisinopril | 482 | 102 |
| Omeprazole | Omeprazole | 453 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 434 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 395 | 76 |
| Metformin Hcl | Metformin Hcl | 381 | 106 |
| Eliquis | Apixaban | 349 | 48 |
| Donepezil Hcl | Donepezil Hcl | 330 | 53 |
| Trazodone Hcl | Trazodone Hcl | 311 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 303 | 46 |
| Famotidine | Famotidine | 299 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 51 |
| Jardiance | Empagliflozin | 266 | 39 |
| Spironolactone | Spironolactone | 259 | 50 |
| Warfarin Sodium | Warfarin Sodium | 247 | 25 |
| Meloxicam | Meloxicam | 243 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 58 |
| Simvastatin | Simvastatin | 229 | 58 |
| Allopurinol | Allopurinol | 209 | 50 |
| Memantine Hcl | Memantine Hcl | 208 | 32 |
| Tramadol Hcl | Tramadol Hcl | 203 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 201 | 31 |
| Alendronate Sodium | Alendronate Sodium | 179 | 38 |
| Ozempic | Semaglutide | 169 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 54 |
| Glimepiride | Glimepiride | 154 | 39 |
| Pregabalin | Pregabalin | 154 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 70 |
| Farxiga | Dapagliflozin Propanediol | 152 | 27 |
| Celecoxib | Celecoxib | 145 | 36 |
| Levetiracetam | Levetiracetam | 145 | 17 |
| Irbesartan | Irbesartan | 143 | 33 |
| Lorazepam | Lorazepam | 143 | 40 |
| Mirtazapine | Mirtazapine | 140 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 32 |
| Potassium Chloride | Potassium Chloride | 135 | 37 |
| Carvedilol | Carvedilol | 132 | 30 |
| Alprazolam | Alprazolam | 126 | 29 |
| Bupropion Xl | Bupropion Hcl | 124 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 106 | 22 |
| Buspirone Hcl | Buspirone Hcl | 101 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 20 |
| Montelukast Sodium | Montelukast Sodium | 95 | 24 |
| Finasteride | Finasteride | 94 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 27 |
| Myrbetriq | Mirabegron | 92 | 17 |
| Ezetimibe | Ezetimibe | 91 | 23 |
| Temazepam | Temazepam | 89 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 24 |
| Clonazepam | Clonazepam | 81 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 18 |
| Bumetanide | Bumetanide | 78 | 19 |
| Baclofen | Baclofen | 77 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 11 |
| Rybelsus | Semaglutide | 75 | 15 |
| Benazepril Hcl | Benazepril Hcl | 73 | 19 |
| Valsartan | Valsartan | 72 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 32 |
| Propranolol Hcl | Propranolol Hcl | 62 | 12 |
| Atenolol | Atenolol | 61 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 59 | suppressed |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 13 |
| Nystatin | Nystatin | 53 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 15 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Hydrocortisone | Hydrocortisone | 46 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Gemtesa | Vibegron | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Prednisone | Prednisone | 41 | 24 |
| Spiriva Respimat | Tiotropium Bromide | 41 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 37 | 11 |
| Loperamide | Loperamide Hcl | 36 | 17 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Nyamyc | Nystatin | 31 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 20 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Clonidine | Clonidine | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Levetiracetam Er | Levetiracetam | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Lactulose | Lactulose | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 16 |
| Diazepam | Diazepam | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 14 |
| Roflumilast | Roflumilast | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,995.43 · 126 records | PFIZER INC. | ABRYSVO, AUSTEDO XR, Adempas, CAPLYTA, COMIRNATY, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LOREEV XR, MOUNJARO, NURTEC ODT, OPSUMIT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error